RNTX News & Events

Rein Therapeutics announced that it has received orphan drug designation from the European Medicines Agency, EMA, for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis, IPF. The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products, COMP, and subsequent adoption by the European Commission.

Rein Therapeutics announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein's lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis, IPF. The preprint, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study." The report describes how inhaled LTI-03 was evaluated in IPF patients to assess safety, pharmacokinetics, and biological activity. According to the authors, LTI-03 was generally well tolerated, and samples collected from treated patients showed reductions in multiple fibrosis-associated biomarkers. These biomarkers include proteins and inflammatory signals linked to disease progression, offering evidence that the drug is reaching the lung and engaging its intended targets.